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http://dx.doi.org/10.1016/j.stemcr.2017.01.011SUMMARYNumerically the most important risk factor for the development of Parkinson’s disease (PD) is the presence of mutations in the glucocer-
ebrosidase GBA1 gene. In vitro and in vivo studies show that GBA1mutations reduce glucocerebrosidase (GCase) activity and are asso-
ciated with increased a-synuclein levels, reflecting similar changes seen in idiopathic PD brain. We have developed a neural crest stem
cell-derived dopaminergic neuronal model that recapitulates biochemical abnormalities in GBA1mutation-associated PD. Cells showed
reduced GCase protein and activity, impaired macroautophagy, and increased a-synuclein levels. Advantages of this approach include
easy access to stem cells, no requirement to reprogram, and retention of the intact host genome. Treatment with a GCase chaperone
increased GCase protein levels and activity, rescued the autophagic defects, and decreased a-synuclein levels. These results provide
the basis for further investigation of GCase chaperones or similar drugs to slow the progression of PD.INTRODUCTION
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder currently affecting 4% of the population >80 years
and whose prevalence is expected to double by 2030 (de
Lau and Breteler, 2006). Multiple neurotransmitter systems
are involved in the neurodegeneration of PD, but the loss of
substantia nigra dopaminergic neurons is responsible for
the dominant early motor features. The pathological hall-
mark of PD is the accumulation and aggregation of a-synu-
clein and the deposition of Lewy bodies. A heterogeneous
range of etiologically and pathogenically relevant factors
have been identified for PD, and it is likely that the neuro-
degeneration and clinical manifestations of the disease are
the end result of multiple aberrant pathways (Schapira and
Jenner, 2011). Several single gene defects have been
identified in familial and apparently sporadic PD (Volta
et al., 2015). Numerically the most important genetic risk
factor for PD is the presence of mutations of the glucocere-
brosidase gene GBA1 (Sidransky et al., 2009). Although
precise estimates vary between populations, approximately
5%–10% of PD patients carry GBA1 mutations, their pres-
ence increasing the risk for PD in any one individual by
20–30 times (Beavan and Schapira, 2013).
Homozygous GBA1 mutations are the cause of the auto-
somal recessive lysosomal storage disorder Gaucher disease
(GD). Both homozygous and heterozygous GBA1mutation
carriers have a similar risk for the development of PD in later
life, although onset in GD patients may be earlier (Alcalay
et al., 2014). The PD expressed in GBA1-positive patients
is clinically indistinguishable from sporadic PD, except for
slightly earlier onset andmore cognitive dysfunction. Phar-
macological responses are identical, imaging and pathology
being the same as for sporadic PD (Schapira, 2015).728 Stem Cell Reports j Vol. 8 j 728–742 j March 14, 2017 j ª 2017 The Aut
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which GBA1 mutations and reduced activity of the gluco-
cerebrosidase enzyme (GCase) increase the risk for PD. A
reciprocal relationship betweenGCase activity and a-synu-
clein levels has emerged as an important candidate that
may influence the development and progression of PD pa-
thology (Sardi et al., 2015). There are several potential pro-
cesses by which reduced GCase activity may result in
increased a-synuclein levels and vice versa, including
GCase trafficking defects, lysosomal dysfunction, substrate
accumulation, and disordered lipid membrane function
(Siebert et al., 2014).
To investigate further biochemical effects of GBA1muta-
tions, we have developed dopaminergic neuronal lines
from neural crest stem cells (NCSCs) obtained from PD
and GBA1 mutation subjects. This model has also been
used to examine the potential to manipulate the GCase/
a-synuclein interaction to provide candidate molecules
for further investigation as disease-modifying therapies in
PD. We demonstrate that these patient-derived dopami-
nergic cells recapitulate the main biochemical abnormal-
ities seen in PD postmortem brain and that through the
use of a small-molecule chaperone, GCase activity can be
increased and a-synuclein levels reduced.RESULTS
Isolation and Characterization of Human Adipose
Neural Crest Stem Cells
Anti-aP2 antibody immunostaining was used to localize
stem cell niches in blood vessel walls of human adipose tis-
sues (Figure 1A), a feature consistent with previous observa-
tions (Shan et al., 2013). Anti-p75 neurotrophin receptorhors.
ns.org/licenses/by/4.0/).
Figure 1. Identification, Isolation, and Characterization of Neural Crest Stem Cells from Human Adipose Tissues
(A) An anti-adipose protein 2 (aP2) antibody (green) was used to identify stem cell niches in human fat tissue.
(B and C) Two antibodies (anti-p75NTR and SOX10, both red) were employed for co-immunostaining with the anti-aP2 antibody in human
adipose tissues, which revealed that some cells express p75NTR and SOX10 in the human adipose stem cell niche.
(D and E) Three to five days after explanting, human adipose tissue showed p75NTR- and SOX10-expressing cells (both red) migrating from
the tissue.
(legend continued on next page)
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(p75NTR) and anti-SOX10 (SOX10) antibodies were used
to confirm that adipose stem cell niches contained NCSCs
(Figures 1B and 1C). p75NTR is a nerve growth factor recep-
tor highly expressed in NCSCs, and has been used to isolate
NCSCs from neural tube in embryonic day 10 (E10) and E9
mice (Stemple and Anderson, 1992); SOX10 is a member
of a transcription factor family (SRY-related HMG box)
involved in the determination of NCSC fate and is highly
expressed in NCSCs (Kim et al., 2003).
We explanted fresh human fat biopsy samples onto a
6-well plate pre-coated with fibronectin and provided en-
ergy-rich medium to enhance stem cell migration. After
3–5 days of explantation, the stem cells continuing to ex-
press p75NTR and SOX10 migrated from fat tissue (Figures
1D and 1E). After 3–4 weeks of explantation (Figure 1H),
the migrated stem cells were detached using enzymatic
methods, passaged, and cryopreserved. Human adipose
NCSCs (haNCSCs), unlike their animal counterparts, are
able to regenerate ex vivo under feeder-free conditions
(Thomas et al., 2008). We cultured and maintained the
stem cells under feeder-free conditions for more than
18 months with over 24 cell passages and confirmed
continuing p75NTR and SOX10 expression (Figures 1F
and 1G).
The ability to form neurospheres has been used to test
ontogeny and multipotency of NCSCs (Nagoshi et al.,
2008). haNCSCs from a range of passages were cultured
in a serum-free sphere-forming medium supplemented
with human epidermal growth factor, human fibroblast
growth factor 2, and B27 supplement. Cells were main-
tained in the same medium for a further 6 days. Multiple
neurospheres were formed (Figure 1I) and expressed the
cell proliferation marker 5-bromo-20-deoxyuridine (BrdU),
neural progenitor maker nestin, immature neuron marker
b-III tubulin, and neural crest cell marker p75NTR (Figures
1J–1L).
The pluripotent gene expression profile is varied depend-
ing on which stage the haNCSCs were isolated. If haNCSCs
are isolated from the pre-migratory state in embryos, the
gene expression profile is highly similar to that of human
embryonic stem cells (ESCs) (Thomas et al., 2008). When
haNCSCs are isolated from adult human neural crest-(F and G) Migrated cells were cultured and maintained under feeder
passages and still expressed p75NTR and SOX10 (both red).
(H) Three-week-old human adipose explant showing numerous cells t
(I) Neurospheres formed after 6 days of culturing in neurosphere form
(J) The cell proliferation marker BrdU (red).
(K and L) The neuronal marker b-III tubulin (red) and the neuronal pr
Nuclei were stained with DAPI (blue).
(M) The pluripotent gene expression in haNCSC was examined by real
adipose-derived stem cells. Relative expression values are plotted as
Scale bars, 50 mm.
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are substantially different to human ESCs (Hauser et al.,
2012). We used real-time qRT-PCR to examine the expres-
sion of six main pluripotent genes, OCT4, SOX2, NANOG,
REX, cMyc, and KLF4, in haNCSCs; and compared their
expression with those in a human ESC line (SHEF-6). We
found that OCT4, SOX2, NANOG, and REX1 are expressed
at lower levels in haNCSCs compared with that in human
ESCs, in agreement with previous studies (Hauser et al.,
2012), while cMycwas expressed at the same level of human
ESCs and KLF4 was expressed at a higher level compared
with human ESCs (Figure 1M). KLF4 is a transcriptional
regulator of genes critical for epithelial-mesenchymal tran-
sition (Tiwari et al., 2013), which is pre-step of neural crest
cells migrating to various elected locations during embryo
development (Nagoshi et al., 2008). As we used the migra-
tion procedure to isolate haNCSCs, the higher level of
KLF4 in haNCSCs than ESCs is to be expected.
A recent study comparing regulatory programs between
neural crest cells and early ESCs found that neural crest
cells retain core pluripotency genes (Buitrago-Delgado
et al., 2015). We therefore examined the expression of the
pluripotent genes NANOG, OCT4, SSEA4, and TRA-1-81,
and the neural crest genes p75NTR and SOX10. HaNCSCs
were isolated from age-matched controls, individuals
with heterozygous GBA1 (N370S/WT) mutations, and spo-
radic PD patients (for details see Table S1). The results
showed that pluripotent and neural crest genes were ex-
pressed in all haNCSC lines, indicating that they retain
neural crest cell features and pluripotent properties (Figures
S1A–S1C). There were no differences in the expression of
these genes between the haNCSC lines. Sonic hedgehog
(SHH) is a signaling molecule that has been found to be
involved in the development of early neural crest progeni-
tors (Brito et al., 2006; Wada et al., 2005) and promotes the
formation of multipotent progenitors endowed with both
neural-melanocytic and mesenchymal differentiation po-
tential (Calloni et al., 2007; Le Douarin et al., 2004). SHH
executes its functions through a cell-surface transmem-
brane protein called Patched (PTCH) and a membrane-
spanning receptor called Smoothened (SMO).We therefore
examined the expression of PTCH and SMO in three groups-free conditions for more than 18 months with more than 24 cell
hat migrated from the tissue.
ation medium.
ogenitor maker nestin (green) were expressed in the neurospheres.
-time qRT-PCR and compared with human ESC line (SHEF-6). ADSC,
means ± SEM from three independent experiments (n = 3).
of haNCSCs with flow cytometry analysis. More than 60%
of cells stained positive with both PTCH and SMO proteins
(Figure 1D), and there were no significant differences in the
levels of these proteins between three haNCSC groups.
These data support the conclusion that adult human adi-
pose tissue contains a cell population that retains neural
crest cell features and can be isolated with a simple migra-
tion protocol.
Dopaminergic Neuronal Differentiation of haNCSCs
Amouse stromal cell (PA6) line has been shown to be able to
induce ESCs to form midbrain dopaminergic neurons (Ka-
wasaki et al., 2000). We therefore initially used PA6 cells
for haNCSC dopaminergic neuronal differentiation via a
co-culture procedure. After co-culturing with a PA6 cell
line for 40 days, haNCSCs were successfully induced to
dopaminergic neurons, which express midbrain dopami-
nergic neuronal makers such as tyrosine hydroxylase (TH)
(Figure 2A), dopamine transporter (DAT) (Figure 2A), LIM-
homeobox transcription factor 1 (LMX1) (Figure 2A), nu-
clear receptor-related protein 1 (NURR1) (Figure 2A), and a
general neuronalmarker, b-III tubulin (Figure 2A).However,
to generate more pure dopaminergic haNCSC cultures, we
used a defined dopaminergic neuronal differentiation pro-
gram proven to be able to generate midbrain dopaminergic
neurons from humanmesenchymal stem cells (Trzaska and
Rameshwar, 2011). During the differentiation cells change
their morphology toward neuron-like cells (Figure 2B),
and express the neuronal marker b-III tubulin after 6 days
(Figure 2C) and the dopaminergic neuronal makers TH
and DATafter 12 days (Figure 2C). Following 40 days differ-
entiation, the neurons become more mature and express
both dopaminergic neuronal markers TH and midbrain
neuronal markers NURR1 (Figure 2D). The proportion of
dopaminergic neurons (TH+) derived from control, hetero-
zygousmutantGBA1, and PD subjects was not significantly
different (Figures 2D and 2E). The percentage of TH+ neu-
rons was 38%–52% (Figure 2E).
To examine the maturation and function of neuronal
cells, we examined the expression of functional ligand-
gated channels in differentiated neurons by measuring
intracellular Ca2+ changes upon application of theneuronal
transmitters (glutamate, dopamine, and N-methyl-D-aspar-
tate [NMDA]) in cells loaded with Fluo-4 AM or Fura-2 AM.
After 40 days of neuronal differentiation, up to 56% of cells
responded to dopamine and 21% responded to glutamate
(Figures 2F and 2G), indicating that haNCSCs can be differ-
entiated to functional dopaminergic neuronal cells.
Establishment of haNCSC-Derived Neuronal Models
of GBA1-Associated PD
To investigate the effects of heterozygous GBA1mutations
on GCase activity and protein levels in neuronal cells, wedifferentiated haNCSC cell lines from wild-type (WT; con-
trol) and heterozygous GBA1 N370S/WT mutation (Table
S1) to dopaminergic neuronal cells using the program
described above. The cells were harvested at different stages
(0, 20, and 40 days) of the differentiation program. The
GCase activity was measured with a fluorogenic assay,
and GCase protein level was determined by western blot-
ting. The results showed that both the protein level and
activity of GCase increased significantly in the WT stem
cell-derived neurons compared with undifferentiated
stem cells during differentiation (Figures 3A–3C). These
increases did not occur in GBA1 mutant (N370S/WT)
haNCSC-derived neurons (Figures 3A–3C).
Induced pluripotent stem cell (iPSC)-derived neurons
from GBA1 mutation patients show reduced GCase enzy-
matic activity and protein levels (Schondorf et al., 2014).
To validate and compare the abnormality seen in the
haNCSC-derived heterozygous GBA1 mutant neurons,
we generated iPSCs from fibroblasts from control subjects
and subjects heterozygous for the N370S GBA1 mutation
(Okita et al., 2011). The iPSC clones from both control
and mutant subjects expressed pluripotent genes
(NANOG, SSEA4, TRA-1-81, and OCT4), and the expres-
sion of the pluripotent genes between control and GBA1
mutation subjects was not significantly different (Fig-
ure S2A). Karyotyping results revealed that no transloca-
tions had occurred during cloning of iPSC (Figure S2C).
The iPSC stem cells were differentiated into dopaminergic
neurons expressing the neuronal marker (b-III tubulin)
and dopaminergic neuronal markers TH and Nurr1
(Figure S2B). Although the pluripotent properties of
iPSC clones were not significantly different between
control subjects and subjects heterozygous for the GBA1
mutation, the GCase activity and protein level were
significantly reduced in neurons derived from subjects
heterozygous for the GBA1 mutation differentiation (Fig-
ures 3D–3F). These results are not only consistent with
the previous iPSC studies, but also confirm the abnormal-
ity seen in the haNCSC-derived heterozygous GBA1
mutant neurons (Figures 3A–3C). The level of b-III tubulin
expression in the haNCSC-derived neurons is constant
at 40–50 days of differentiation, suggesting that the
neuronal cell population is stable at this time in both con-
trol and GBA1mutation subjects (Figures 3G and 3H). We
therefore selected this time period to examine the effects
of therapeutic intervention with ambroxol.
Heterozygous GBA1Mutations Decrease GCase
Activity and Protein Levels in Human Neurons
A recent study using iPSCs with homozygous GBA1muta-
tions described widespread lysosomal depletion (Awad
et al., 2015). To investigate the effects of heterozygous
GBA1 mutations on GCase activity, we differentiatedStem Cell Reports j Vol. 8 j 728–742 j March 14, 2017 731
Figure 2. Dopaminergic Neuronal Differentiation of haNCSCs
(A) The mouse PA6 cell line was used for dopaminergic neuronal differentiation via a co-culture procedure. After co-culturing for 40 days,
human adipose neural crest stem cells expressed the dopaminergic neuronal makers tyrosine hydroxylase (TH, red) and the dopamine
transporter (DAT, red), the midbrain markers LIM-homeodomain transcription factor (LMX1, red), and nuclear receptor-related protein 1
(Nurr1, red) and the pan-neuronal marker b-III tubulin (green).
(B) When a defined program was used to differentiate adipose neural crest stem cells into dopaminergic neurons, the cells gradually
changed their morphology toward neuron-like cells.
(C) Western blot experiments showed that pan-neuronal (b-III tubulin) and dopaminergic neuronal makers (TH, DAT) were expressed after
20 days of defined neuronal differentiation.
(D and E) After 40 days of defined neuronal differentiation, the percentage of TH+ neurons was 38%–52%. The proportion of TH+ neurons
derived from wild-type (WT) control, heterozygous mutant GBA1, and iPD subjects was not significantly different. For all three groups n = 3
cell lines, and data are represented as mean ± SEM.
(F and G) The expression of functional ligand-gated channels in differentiated neurons was examined by measuring cytosolic Ca2+ changes
(bright) upon application of the neural transmitters (glutamate, dopamine, and NMDA) in cells loaded with Fluo-4 AM or Fura-2 AM. After
40 days of defined neuronal differentiation, up to 56% of cells responded to dopamine (DA), 21% responded to glutamate (Glu), and 16%
responded to NMDA. Nuclei were stained with DAPI (blue). AFU, arbitrary fluorescence units.
Scale bars, 50 mm.
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Figure 3. Establishment of haNCSC-Derived Neuronal Models of GBA1-Associated PD
(A and B) Control and N370S/WT haNCSC lines were differentiated to dopaminergic neurons with the defined program. The GCase protein
levels increased significantly in control haNCSC-derived neurons during differentiation, but were not increased in GBA1 mutant (N370S/
WT) haNCSC-derived neurons.
(C) The activity of GCase also increased significantly in control haNCSC-derived neurons during differentiation, but this increase was not
seen in GBA1 mutant (N370S/WT) haNCSC-derived neurons.
(D–F) Likewise, the GCase protein levels and activity in the iPSC-derived neurons increased significantly during differentiation in control
subjects but not in subjects heterozygous for the GBA1 mutation.
(G and H) By examining the neuronal marker b-III tubulin in the differentiated cells, it was found that 40–50 days of differentiation is the
optimal time window to examine the effects of therapeutic interference.
Data are presented as means ± SEM from three independent experiments (n = 3). **p < 0.01; NS, not significant (p > 0.05). All comparisons
were carried out with one-way ANOVA and Student’s t test.haNCSCs derived from controls and subjects heterozy-
gous for the GBA1 mutation (N370S/WT) and idiopathic
PD (iPD) into dopaminergic neurons with the established
differentiation program for 40 days. GCase activity was
significantly reduced by 40.2% (p = 0.0307) in the GBA1
mutation group compared with control. GCase activity
was not reduced in the iPD-derived neurons (Figure 4A).
Hexosaminidase activity, another lysosomal enzyme,
was not significantly different in the different cell lines
(Figure 4B). The GCase protein level in N370S/WT stem
cell-derived neurons was significantly decreased by
61.3% (p = 0.0257) compared with WT (Figures 4C and
4E), consistent with previous iPSC-derived neuronal
studies (Schondorf et al., 2014). There was a trend for
the GCase protein level in idiopathic PD stem cell-derived
neurons to be decreased, but this was not statistically
significant.GBA1Mutation Increased a-Synuclein Level in
haNCSC-Derived Dopaminergic Neurons
Inhibition of GCase led to the accumulation of a-synu-
clein in in vitro and in vivo models (Cleeter et al.,
2013; Manning-Bog et al., 2009). The iPSC-derived
neuronal model from both GD and heterozygous GBA1
mutant demonstrated accumulation of a-synuclein
(Mazzulli et al., 2011). In our model, the level of a-syn-
uclein was significantly increased by 172% (p = 0.02) in
the neurons derived from GBA1 mutation haNCSC-
derived dopaminergic neurons compared with controls
(Figures 4D and 4F). Immunocytochemistry in the
GBA1 mutant (N370S/WT) human neurons showed
that the level of a-synuclein protein was higher in the
dopaminergic as opposed to the non-dopaminergic cells
in culture (Figures 4G and 4H). There was a trend for the
level of a-synuclein in the idiopathic PD group to beStem Cell Reports j Vol. 8 j 728–742 j March 14, 2017 733
Figure 4. GBA1 Mutation Decreases GCase Activity and Protein Levels and Increases a-Synuclein in haNCSC-Derived Dopaminergic
Neurons
(A, C, and E) HaNCSCs derived from controls (CTRL, C1–3), carriers of the heterozygous GBA1mutation (N370S/wt; Het1–3), and idiopathic
Parkinson’s disease (iPD1–3) patients were differentiated into dopaminergic neurons for 40 days. GCase activity and the level of GCase
protein were significantly lower in the GBA1 mutation group, but not in the iPD group, compared with the control group. For all three
groups n = 3 cell lines; data are represented as mean ± SEM.
(B) Hexosaminidase, another lysosomal enzyme, was not affected by the GBA1 mutation. For all three groups n = 3 cell lines; data are
represented as means ± SEM.
(D and F) The level of a-synuclein was significantly increased in the GBA1 mutation group, but not in iPD group, compared with the
control group. For both control and iPD groups n = 3 cell lines; for the GBA1mutation group (Het1–4) n = 4 cell lines; data are represented
as mean ± SEM.
(G and H) The level of a-synuclein protein (red) was identified in the untreated GBA1mutant (N370S/WT) human neurons. Results indicate
that dopaminergic neurons (TH+, green) have a higher level of a-synuclein protein. Nuclei were stained with DAPI (blue).
All comparisons were carried out with one-way ANOVA and Student’s t test. *p < 0.05; NS, not significant (p > 0.05). Scale bars, 10 mm.elevated, but this did not reach statistical significance
(Figures 4D and 4F).
GBA1Mutation Impaired Macroautophagy in
haNCSC-Derived Dopaminergic Neurons
Postmortem PD brain (Murphy et al., 2014) and an iPSC-
derived neuronal model from GBA1 mutant PD patients
(Schondorf et al., 2014) suggested that GCase deficiency
may cause general autophagic dysfunction and disruption
of the autophagy-lysosome pathway. We found that basal
levels of light chain type 3-II protein (LC3-II), a marker of
autophagosomes, were decreased, but not significantly so,
in GBA1 mutation-positive carrier neurons compared
with control neurons (Figures 5A and 5B). The decrease of
LC3-II inGBA1mutation-positive carrier neurons suggests,
but does not confirm, that the N370S GBA1 mutation im-
pairs autophagosome formation.734 Stem Cell Reports j Vol. 8 j 728–742 j March 14, 2017P62 is a ubiquitin-binding scaffold protein acting as a
cargo receptor recruited to the autophagosome membrane
through interaction with LC3-II (Itakura and Mizushima,
2011), and is an alternativemarker for detecting autophagic
flux (Bjorkoy et al., 2005). P62 levels were decreased 62%
(p = 0.0162) in GBA1 mutant neurons (Figures 5C and
5D). To examine whether the decrease in LC3-II and p62
is due to a defect of the fusion of autophagosomes with ly-
sosomes or to dysfunction of autophagosome formation,
we inhibited themacroautophagy pathway at the autopha-
gosome-lysosome fusion stage with bafilomycin. The re-
sults (Figures 5E–5H) showed that LC3-II and p62 protein
levels were increased significantly after bafilomycin treat-
ment. This indicates that the autophagosome-lysosome
fusion pathway was normal and that the decrease in LC3-
II and p62 protein levels in GBA1 mutation neuronal cells
are most likely due to impaired autophagosome formation.
Figure 5. HaNCSC-Derived Dopaminergic
Neurons from GBA1 Mutant Carriers Show
Defective Lysosomal Autophagy
(A and B) LC3-II appeared decreased in the
GBA1 mutation group (N370/wt; Het1–3)
compared with the control (C1–3; CTRL) and
iPD (PD1–3) groups, but the decrease was not
statistically significant.
(C and D)The ubiquitin-associated protein
p62 was significantly decreased in the GBA1
mutation group compared with the other two
groups.
(E–H) When the neurons were incubated with
the inhibitor of autophagy bafilomycin, the
LC3-II and p62 level increased significantly,
indicating that the fusion of lysosomes with
autophagosome was normal but the auto-
phagosome number was reduced by the GBA1
mutation; i.e., the creation of autophago-
somes in the GBA1 mutant neurons was
decreased.
For all three groups n = 3 cell lines; data are
presented as means ± SEM. All comparisons
were carried out with one-way ANOVA and
Student’s t test. **p < 0.01; *p < 0.05; NS,
not significant (p > 0.05).GBA1Mutation Does Not Affect LAMP2a or LAMP1
There was no significant change in levels of the chaperone-
mediated autophagy (CMA) protein LAMP2a or LAMP1 in
GBA1mutation carrier neurons when compared with con-
trol cells (Figures S3A–S3D).
Ambroxol Treatment Increases GCase Activity and
Protein Levels
Ambroxol is a GCase small-molecule chaperone that has
been reported to increase the expression of the TFEB tran-
scription factor (McNeill et al., 2014). Ambroxol was incu-
bated for 6 days with 40-day differentiated dopaminergic
neurons derived from haNCSCs and induced a significant
increase in GCase activity (CTRL 34.8% [p = 0.164], GBA1
mutation 70.6% [p = 0.0004], and iPD 28.6% [p = 0.016])
and protein levels (CTRL 65.2% [p = 0.026],GBA1mutation
330.2% [p = 0.009], and iPD 190.7% [p = 0.050]) in all
tested lines (Figures 6A, 6B, and 6D). Any contribution
from non-lysosomal GCase (GBA2) was identified by using
the inhibitor conduritol-B-epoxide (CBE) (Figure 6B). CBE
inhibition of the haNCSC-derived neuronal cell lines ledto 90% GCase inhibition in all cell lines. There was no
significant change in hexosaminidase activities after am-
broxol exposure (Figure 6C).
Ambroxol Reduces a-Synuclein Levels in GBA1
Mutant Neurons
A significant increase in a-synuclein protein levels was
found in 40-day-old GBA1 mutation-positive haNCSC-
derived neurons carrying the N370S allele compared with
controls (Figure 4F). Following ambroxol treatment, there
was a significant reduction in a-synuclein levels in the
GBA1 mutation neurons (by 83%, p = 0.025). a-Synuclein
levels were also reduced in control and iPD neurons, but
these did not reach significance (35% [p = 0.316] and
39% [p = 0.267], respectively) (Figures 6E and 6F). a-Synu-
clein mRNA levels were not affected in any of the neuronal
lines before or after ambroxol treatment (Figure 6G).
Immunochemical staining of a-synuclein in untreated
N370S mutant neurons (Figures 6K and 6L) and treated
N370S mutant neurons (Figures 6M and 6N) indicated
that ambroxol reduced a-synuclein levels in neurons.Stem Cell Reports j Vol. 8 j 728–742 j March 14, 2017 735
Because it has been reported that cathepsin D is impor-
tant in the degradation of a-synuclein (Sevlever et al.,
2008), we investigated whether ambroxol modulated the
level of this protein in the patient-derived cells. We found
that the level of mature cathepsin D protein in GBA1
mutant (N370S/WT) neurons increased following am-
broxol treatment (Figures 6I and 6J).Ambroxol Treatment Upregulates Macroautophagy
and Rescues Autophagy
Following 6 days of ambroxol treatment, there was an up-
regulation of macroautophagy with significant increases
seen in both LC3-II (Figures 7A and 7C) and p62 (Figures
7B and 7D) protein levels in GBA1 mutation-positive and
iPD neurons. Incubation of differentiated neurons with ba-
filomycin for 4 hr caused a further increase in LC3-II and
p62 protein in all lines (Figures 7G–7J), indicating that
ambroxol-increased LC3-II and p62 was not due to
blockade of the autophagosome-lysosome fusion pathway.
LC3B mRNA levels were not significantly increased after
ambroxol treatment (Figure 7E). p62 mRNA was signifi-
cantly increased in the PD group after ambroxol treatment;
there was a trend toward increased GBA1mutant neurons,
but this did not reach significance (Figure 7F). Ambroxol
did not affect hexosaminidase activity (Figure 6C) or levels
of LAMP1 and LAMP2a (Figures S4A–S4D).DISCUSSION
Our study describes the preparation and analysis of
dopaminergic neurons from NCSCs isolated from human
adipose tissue, their use in the investigation of the
biochemical consequences of the GBA1 N370S mutation,
and the potential for the small-molecule GCase chaperone,
ambroxol, to reverse these effects. The use of haNCSCs pro-
vides direct access to pluripotent stem cells and provides an
alternative source to those derived from fibroblast lines for
the creation of neuronal lines. The haNCSC approach has
advantages in terms of ease of access to neural crest cells,
no requirement to reprogram, retention of the intact host
genome, simple protocols for neuronal differentiation,
production of homogeneous colonies, and less cost.
We have used this technique to develop both haNCSCs
and iPSCs from controls and patients with the N370S
GBA1 mutation that causes GD and increases the risk for
PD. Cell lineages were differentiated into dopaminergic
neurons and compared with data from iPSCs derived
from fibroblasts from the same donors. Compared with
controls, the N370S mutant lines from both sources
showed reduced GCase activity and protein levels and
increased a-synuclein levels. These results are in agreement
with a previous study using PD-derived iPSCs (Schondorf736 Stem Cell Reports j Vol. 8 j 728–742 j March 14, 2017et al., 2014). We also show that the small-molecule GCase
chaperone ambroxol can rescue GCase activity and reduce
a-synuclein levels in human neurons. A recent study (Maz-
zulli et al., 2016) used a non-inhibitory small modulator to
activate GCase in synucleinopathy culture model and
found that activation of GCase enhanced the clearance of
pathological a-synuclein. These findings support the hy-
pothesis that increasing GCase activity reduces a-synuclein
levels in dopaminergic neurons, and has significant impli-
cations for the use of GCase chaperones as treatments to
reduce a-synuclein in PD patients.
Our results also have several important implications for
the future study ofGBA1mutations in PD. The ability easily
to generate dopaminergic neurons from stem cells derived
directly from the host provides an important source for the
study of the biochemical consequences of GCase defi-
ciency. We show that the N370S mutation reduces GCase
protein levels and activity, and is associated with elevated
a-synuclein levels. These are the core biochemical features
in the study of GBA1 mutations in PD as expressed in PD
brain (Gegg et al., 2012) and provide a model with which
to test therapeutic interventions to manipulate the
GCase-a-synuclein pathway.
We show that the GCase defect was associated with
impaired autophagosome formation in the N370S GBA1
mutation dopaminergic haNCSCs, in agreement with
Schondorf et al. (2014). We have shown that ambroxol res-
cues the biochemical abnormalities resulting from the
N370S mutation. Ambroxol increased GCase activity in
GD and PD fibroblasts and reduced a-synuclein levels
in SHSY-5Y cells (McNeill et al., 2014). Ambroxol has
also been shown to activate transcription factor EB and
therefore to induce transcriptional upregulation of the
CLEAR (coordinated lysosomal expression and regulation)
network and saposin C levels (Ambrosi et al., 2015;McNeill
et al., 2014). In the dopaminergic neuronal model derived
from haNCSCs, ambroxol significantly increased GCase
protein in the idiopathic PD and N370S GBA1 mutant
lines. There were parallel increases in activity in the
N370S and iPD lines, with a trend in the controls that did
not reach significance. We also found that ambroxol can
significantly increase mature cathepsin D protein in
N370S GBA1 mutant lines. This may be a consequence of
the transcriptional effects of ambroxol andmay contribute
to the mechanisms by which this drug reduces a-synuclein
levels. An alternative or additional mechanism for the
reduction in a-synuclein may be an increase in cathepsin
D due to elevated GCase and ceramide levels induced by
ambroxol.
Autophagy is considered to be a dynamic process
comprising three sequential steps: formation of autopha-
gosomes, the fusion of autophagosomes with lysosomes,
and degradation. During this process, cytosolic form of
Figure 6. Ambroxol Treatment Recovers GCase Activity and Increases GCase Protein
(A and D) The level of GCase protein was increased following ambroxol (ABX) treatment in heterozygous GBA1mutant (Het1–3; N370S/wt)
and iPD (PD1–3) neurons, but not in neurons derived from controls (C1–3; CTRL). For all three groups n = 3 cell lines.
(B) Ambroxol treatment significantly increased GCase activity in all three groups of neurons. Addition of the GCase inhibitor, conduritol-B-
epoxide (CBE), showed that the contribution to the increase from non-lysosomal GCase (GBA2) was minimal. For all three groups n = 3 cell
lines.
(C)The activity of hexosaminidase was not affected by ambroxol treatment. For all three groups n = 3 cell lines.
(legend continued on next page)
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LC3 is conjugatedwith phosphatidylethanolamine to form
LC3-II, which is recruited to autophagosome membranes.
p62 is a ubiquitin-binding scaffold protein acting as a cargo
receptor, which is recruited in the formation of autophago-
somes (Itakura and Mizushima, 2011). Ambroxol treat-
ment significantly increased the steady-state levels of
both LC3-II and p62 proteins in our model, suggesting
that ambroxol increases autophagy by promoting autopha-
gosome formation and turnover. This interpretation is
further supported by a substantial increase in p62 mRNA.
The unaltered LC3B gene expression suggests that the in-
fluence of ambroxol on LC3 synthesis is minimal.
The autophagic pathway has been increasingly impli-
cated in a number of neurodegenerative diseases including
PD (Mizushima et al., 2008), and the deregulation of auto-
phagy is evident in the brains of PD patients (Levy et al.,
2009). Autophagy has three different pathways, namely
macroautophagy, microautophagy, and CMA. Previous
studies have found that both macroautophagy and CMA
pathways contribute to a-synuclein degradation in primary
postnatal ventral midbrain neurons (Xilouri et al., 2008).
Directly applying bafilomycin A1, an inhibitor of auto-
phagy, to the cortex of a-synuclein transgenic mice
increased a-synuclein levels in brain (Ebrahimi-Fakhari
et al., 2012), suggesting that the autophagic pathway plays
an important role in degradation of a-synuclein in neu-
rons. Ambroxol treatment restores autophagosome forma-
tion in GBA1 mutant lines, which in turn would enhance
the degradation of a-synuclein and contribute to the
decreased a-synuclein levels in the GBA1 mutant lines.
These results are important in confirming in patient-
derived dopaminergic neuronal cells that ambroxol can
rescue defects due to GCase deficiency, and appears to do
so by several mechanisms. The reduction in neuronal
a-synuclein levels offers the potential for ambroxol or
similar drugs to be tried as a disease-modifying therapy in
PD patients with GBA1 mutations (Schapira and Gegg,
2013). The strategy to reduce a-synuclein in PD is common(E and F) Ambroxol treatment (60 mM) significantly decreased a-synuc
a-synuclein protein also occurred in treated WT and iPD neurons, but t
lines; for the GBA1 mutant group n = 4 cell lines.
(G) The a-synuclein mRNA level in all three groups of neurons was not a
lines; for GBA1 mutant group n = 4 cell lines.
(H) There was no significant difference in the amount of a-synuclein re
all three groups. For control and iPD groups n = 3 cell lines; for GBA1
(I and J) Mature cathepsin D protein level was significantly increased
neurons. For all groups n = 3 cell lines.
(K and L) High level of a-synuclein protein (red) was seen in untreat
(M and N) The lower level of a-synuclein protein (red) was seen in the
marker b-III tubulin was stained green. Nuclei were stained with DAP
Data are presented as means ± SEM. All comparisons were carried out w
not significant (p > 0.05). Scale bars, 10 mm.
738 Stem Cell Reports j Vol. 8 j 728–742 j March 14, 2017to a number of approaches to slow progression in PD (Scha-
pira et al., 2014). Ambroxol is currently under investigation
to confirm blood-brain barrier penetration before use in a
larger trial. However, the haNCSC dopaminergic model
used here provides the opportunity to test similar drugs
to manipulate the GCase pathway for neuroprotection
in PD.EXPERIMENTAL PROCEDURES
Subjects and Sample Collection
Samples from ten subjectswere used in the study;written informed
consent was obtained before subcutaneous fat was collected. The
protocols used for collection were approved by the Royal Free
Research Ethics Committee (REC number 10/H0720/21). PD was
diagnosed according to UK Brain Bank criteria (Litvan et al.,
2003). Differences in age and sex between groups were checked us-
ing one-way ANOVA. Skin-punch biopsies containing subcutane-
ous adipose tissues (4 mm in diameter) were obtained from arm
of participants; the subcutaneous adipose tissues were dissected
from skin and used for cell isolation. Ten subjects were divided
into three groups according to their genotype (wt/wt healthy,
N370S/wt, and wt/wt iPD). In some of the experiments we used
four heterozygous mutation lines including three heterozygous
carriers and one heterozygous PD. This was initially to examine
whether there were differences between these cell lines in terms
of changes associated with the GBA1 mutation. We examined
GCase activity, SNCA, and LAMP1 protein level in all of these
four cell lines before and after ambroxol treatment, and found
that the changes in these four cell lines are all similar; we have
not observed any significant differences between heterozygous
carriers and heterozygous PD cell lines. Therefore, we used three
heterozygous carriers for the remainder of the experiments. More
detailed information regarding subjects can be found in Table S1.
Isolation and Maintenance of haNCSCs
Human subcutaneous adipose tissues were washed once with
growth medium and dissected into small pieces (less than 0.2 cm
diameter). The small pieces of adipose tissues were explanted in
fibronectin-coated 6-well plates. A sterilized coverslip was used tolein protein in GBA1mutant (N370S/WT) neurons. The lower level of
he decrease was not significant. For control and iPD groups n = 3 cell
ffected by ambroxol treatment. For control and iPD groups n = 3 cell
leased in the culture medium between treated and untreated cells of
mutant group n = 4 cell lines.
following ambroxol treatment in GBA1 mutant (N370S/WT) human
ed in the GBA1 mutant (N370S/WT) neurons.
ambroxol-treated GBA1 mutant (N370S/WT) neurons. The neuronal
I (blue).
ith one-way ANOVA and Student’s t test. **p < 0.01; *p < 0.05; NS,
Figure 7. Ambroxol Treatment Upregulates Macroautophagy and Rescues the Autophagic Defect
(A–D) Following ambroxol (ABX) treatment, levels of the autophagosome markers LC3-II and p62 were significantly increased in GBA1
mutation (Het1–3; N370S/wt) and iPD (iPD1–3) cell lines, but not in control (C1–3; CTRL) cells.
(legend continued on next page)
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cover the tissue in order to prevent tissue floating in the medium.
Media were changed every 4 days until migrated cells reached
60%–70% confluency. The cells were dissociated from the well
with Accutase (Millipore) and seeded in normal culture dishes
with growth medium. Cells were passaged with a ratio of 1:3
when they reached 70%–80% confluency. At this density, the
growthmediumwas removed; cells were washedwith PBS without
Ca2+ and were incubated with Accutase (1 mL/dish; 1003 20mm)
at 37C for 3–5min. Growthmediumwas added to the dissociated
cells and the medium containing cells was divided over three indi-
vidual dishes. Cells were cultured and maintained in growth me-
dium at 37C with 5% CO2/95% air.
Neurosphere Formation and Maintenance
When haNCSC reached to 70%–80% confluency, cells were disso-
ciated with Accutase at 37C for 3–5 min. Growth medium was
added to the dish to inhibit Accutase activity. Cells were collected
and pelleted by centrifugation at 2003 g for 10min. The cell pellet
was resuspended with neurosphere formation medium, trans-
ferred to an uncoated 12-well plate, and incubated at 37C with
5% CO2/95% air. Neurospheres formed within 24 hr in neuro-
sphere formation medium. The neurospheres were cultured and
maintained in the same conditions with medium changes every
5 days.
Dopaminergic Neuronal Differentiation of haNCSCs
with Co-culture System
PA6 cells were maintained as described previously (Kawasaki et al.,
2000). For differentiation experiments, PA6 cells were seeded on
fibronectin-coated chamber slides 1 day before introducing
haNCSCs into the culture. haNCSCs were harvested and resus-
pended in neurobasal medium supplemented with B27 (13). The
medium was removed from the chamber and PA6 cells were
washed with PBS once. haNCSC cells in neurobasal medium sup-
plementedwith B27were introduced into the chamber with a den-
sity of 200 cells/chamber. Mediumwas changed every 2 days up to
40 days.
Dopaminergic Neuronal Differentiation with Defined
Medium and Quantification
haNCSC were detached with Accutase solution and the Accutase
was neutralized by the addition of growth medium. Cells were
seeded in fibronectin-coated 6-well plates at a density of 2.4 3
104 cells/well (for immunocytochemistry assay, cells were seeded
onto coverslips coated with fibronectin within a 6-well plate)
with growth medium. After 24 hr of seeding, the growth medium
was removed from thewell; cellswerewashed oncewithneurobasal(E) LC3B mRNA levels were not significantly different between treate
(F) p62 mRNA levels were increased in iPD neurons after ambroxol tre
and GBA1 mutation cells.
(G–J) When the macroautophagy pathway was inhibited with bafilom
increased further, indicating that the fusion of lysosomes with autoph
the ambroxol treatment in GBA1 mutation and iPD groups.
For all three groups n = 3 cell lines; data are presented as means ± SEM.
t test. **p < 0.01; *p < 0.05; NS, not significant (p > 0.05).
740 Stem Cell Reports j Vol. 8 j 728–742 j March 14, 2017medium and then cultured with neuronal induction medium. The
cells were cultured with 5% CO2/95% air for 10 days for neuronal
induction. Following neuronal induction, the neuronal induction
mediumwas replacedwith neuronalmaturationmedium. The cells
were cultured with 5% CO2/95% air for 30 days. The volume of
neuronal maturation medium was 1.7–2 mL/well (6-well plate).
The mediumwas changed with the freshlymade neuronal matura-
tion medium every 8 days during maturation. For the purposes of
assessing the percentage of dopaminergic neurons in the differenti-
ated cells, the number of total cells and TH-positive immunostain-
ing neurons were counted. For the three groups each group con-
tained three subjects, three slides of each subject were studied,
and three fields of each slidewere used for counting. The percentage
of dopaminergic neurons was then calculated according to the
counts.
Ambroxol Treatment of haNCSC-Derived Neurons
haNCSC-derived neuronal cultures were treated at day 40 of
neuronal differentiation with ambroxol (A9797, Sigma-Aldrich)
on alternate days for 6 days. Ambroxol was dissolved in DMSO
and further diluted in cell culture medium to give a final concen-
tration of 60 mM. Controls were cultured with medium containing
DMSO instead of ambroxol in DMSO. At day 6, the cells were
washed twice with PBS prior to harvest. Cell pellets were frozen
at 80C for storage.
Statistical Analysis
Data are expressed as mean ± SEM and statistical significance be-
tween groups was determined by one-way ANOVA followed by
the two-tailed t test. A p value of <0.05was considered significantly
different. All data were analyzed by GraphPad Prism 6 statistical
software.
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